Such therapeutic synergy offered by c-MET suppression not only explains why superior sensitivity to radio- and chemotherapy is seen in GBM patients with low-c-MET expression 49, 50 but also provides empirical support for the clinical development of c-MET inhibitors and monoclonal antibody (onartuzumab) as adjuvant therapies for GBM 51. Here, MET is linked to glioblastoma.